These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 22653341)

  • 1. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
    Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
    Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
    Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
    [No Abstract]   [Full Text] [Related]  

  • 5. Seromucinous Tumors of the Ovary. What's in a Name?
    Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2016 Jan; 35(1):78-81. PubMed ID: 26598986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
    Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.
    Lee KR; Nucci MR
    Int J Gynecol Pathol; 2003 Jan; 22(1):42-51. PubMed ID: 12496697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed Ovarian Neoplasms With Gastrointestinal-type Mucinous and Mullerian Epithelial Components: A Rare Group of Tumors Demonstrating the Phenotypic Plasticity of the Mullerian Epithelial Cell.
    Chui MH; Ellenson LH
    Am J Surg Pathol; 2023 Jul; 47(7):756-765. PubMed ID: 37125505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
    Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
    Int J Gynecol Pathol; 2006 Jan; 25(1):83-9. PubMed ID: 16306790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
    Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
    J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
    Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
    Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
    Taylor J; McCluggage WG
    Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Müllerian Mucinous Cystadenomas of the Ovary: A Report of 25 Cases of an Unheralded Benign Ovarian Neoplasm Often Associated With Endometriosis and a Brief Consideration of Neoplasms Arising From the Latter.
    Watkins JC; Young RH
    Int J Gynecol Pathol; 2022 Jan; 41(1):68-75. PubMed ID: 33577227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.